CD274 and neoplasm: Although ICI, such as anti-CTLA4, anti-PD-1/PD-L1, and other molecular-targeted therapies have advanced cancer therapy in recent years, reliable and sensitive protocols for tumor monitoring during such treatments are currently lacking [37].